You are here

  • Home
  • Archive
  • Volume 9, Issue Suppl 2
  • PO.6.137 Design of a phase 2, multicenter, randomized, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of nipocalimab in adults with active systemic lupus erythematosus

Article metrics

Article menu

Download PDFPDF

Friday 07 October 2022 from 13:00 to 14:10
Po.6 E- poster session 6: management and recommendations, old and new therapies/biologics
PO.6.137 Design of a phase 2, multicenter, randomized, placebo-controlled, parallel-group, double-blind study to assess the efficacy and safety of nipocalimab in adults with active systemic lupus erythematosus

 

Online download statistics by month:

Online download statistics by month: September 2022 to March 2024

AbstractFullPdf
Sep 20225207
Oct 2022129014
Nov 202246808
Dec 20221306
Jan 20236204
Feb 202393016
Mar 202323013
Apr 20233806
May 2023803
Jun 20231900
Jul 20231403
Aug 20232005
Sep 20231002
Oct 2023803
Nov 20231703
Dec 20231203
Jan 20242302
Feb 2024804
Mar 20241705
Total10340107